Towards Personalized Vaccines—Tailoring Peptide Vaccines to Demographic Groups and Individuals

Abstract

Traditional vaccines have seen spectacular successes in eradicating smallpox and have come close to eradicating poliomyelitis also. However, they have been short in combating viral epidemics which are now occurring with increasing frequency; the reasons are primarily due to rapid mutations in RNA viruses. Alternative procedures are to be found in the new science of vaccinomics where peptide vaccines have come to be recognized as a strong alternative strategy. While several issues still need to be resolved, and no license has yet been released for human use of peptide vaccines, such vaccines have found ready acceptance in cancer therapeutics where personalized vaccines are of necessity the de facto norm. This knowledge gives us the opportunity in the event of viral epidemics to tailor making vaccines for different communities for maximum efficiency and for immunocompromised individuals. We give a brief perspective on the current status and future prospects of new trends in vaccine research, specifically peptide vaccines development, in this paper.

Current Perspective of Zika Virus and Vaccine Development

“…In another technological approach, Nandy et al 101,102 proposed setting up peptide vaccine labs and production centres at selected locations around the globe. While we have covered in many reviews the different approaches to designing peptide vaccines against pandemic viruses like Zika and COVID-19, several issues need to be resolved in the wet-lab environment before such vaccines can be safely and successfully marketed.…”